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Abstract
Malignant gliomas represent one of the most aggressive types of cancers and their recurrence is closely linked to acquired
therapeutic resistance. A combination of chemotherapy is considered a promising therapeutic model in overcoming
therapeutic resistance and enhancing treatment efficacy. Herein, we show by colony formation, Hochest 33342 and TUNEL
staining, as well as by flow cytometric analysis, that LY294002, a specific phosphatidylinositide-3-kinase (PI3K) inhibitor,
enhanced significantly the sensitization of a traditional cytotoxic chemotherapeutic agent, tamoxifen-induced apoptosis in
C6 glioma cells. Activation of PI3K signaling pathway by IGF-1 protected U251 cells from apoptosis induced by combination
treatment of LY294002 and tamoxifen. Interference of PI3K signaling pathway by PI3K subunit P85 siRNA enhanced the
sensitization of U251 glioma cells to tamoxifen -induced apoptosis. By Western blotting, we found that combination
treatment showed lower levels of phosphorylated Akt
Ser473 and GSK-3b
Ser9 than a single treatment of LY294002. Further, we
showed a significant decrease of nuclear b-catenin by combination treatment. In response to the inhibition of b-catenin
signaling, mRNA and protein levels of Survivin and the other three antiapoptotic genes Bcl-2, Bcl-xL, and Mcl-1 were
significantly decreased by combination treatment. Our results indicated that the synergistic cytotoxic effect of LY294002
and tamoxifen is achieved by the inhibition of GSK-3b/b-catenin signaling pathway.
Citation: Li C, Zhou C, Wang S, Feng Y, Lin W, et al. (2011) Sensitization of Glioma Cells to Tamoxifen-Induced Apoptosis by Pl3-Kinase Inhibitor through the GSK-
3b/b-Catenin Signaling Pathway. PLoS ONE 6(10): e27053. doi:10.1371/journal.pone.0027053
Editor: Jingwu Xie, Indiana University School of Medicine, United States of America
Received March 11, 2011; Accepted October 10, 2011; Published October 27, 2011
Copyright:  2011 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by National Natural Science Foundation of China (No. 31070924), Projects of International Cooperation and Exchanges,
Science and Technology Planning Project of Guangdong Province, China (No. 1011420600004), and Research Fund for the Doctoral Program of Higher Education
of China (No. 20100171110052). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: shxiaoy@mail.sysu.edu.cn (XS); mouyg@mail.sysu.edu.cn (YGM)
Introduction
Malignant gliomas are the most common primary tumors in the
human brain. Despite the conventional treatments that include
surgical resection, radiation therapy, and chemotherapy, frequent
tumor recurrence results in poor prognosis with a mean survival
time of 9–12 months for grade IV and 2 years for grade III glioma
[1]. Exploring new therapeutic modes are, therefore, necessary for
improving the outcomeof glioma treatment.
Tamoxifen, a potent estrogen receptor (ER) antagonist derived
from nonsteroid triphenylethylene, has been extensively used to
treat ER
+ breast cancer. There have been increasing reports
showing that a high dose of tamoxifen(4–8 fold higher than that
for ER+ breast cancers) could be beneficial in the treatment of
ER
2 tumors, including glioma [2,3]. However, in almost all the
trials, only a subgroup of patients with malignant gliomas
responded (response rate of about 30%) or were stabilized with
prolonged treatment of high doses of tamoxifen [4,5].
Although several intracellular signaling pathways, such as
Protein kinase C, transforming growth factor-b, calmodulin, the
transcription factor c-Myc, and the mitogen-activated protein
kinases p38 and c-Jun NH2-terminal kinase have been implicated,
the precise molecular mechanism of ER-independent proapoptotic
activity of tamoxifen remains unclear [6,7,8,9]. A better
understanding of the mechanism of tamoxifen-induced apoptosis
of malignant glioma cells would help improve the sensitivity and
the response of the cells to tamoxifen treatment [10].
The phosphatidylinositide-3-kinase (PI3K)/Akt signaling path-
way might be the best characterized pathway in the transmission
of anti-apoptotic signals for cell survival. PI3K pathways regulate
several malignant phenotypes including antiapoptosis, cell growth,
and proliferation [11]. Activation of PI3K pathway is associated
with poor prognosis in glioma patients [12]. Activated PI3K
phosphorylates several downstream effectors including AKT. Akt
is a critical mediator of PI3K signaling located at an intersection of
multiple pathways involved in cell proliferation, survival, tran-
scription, and metabolic processes [13,14]. Inhibitors of PI3K and
AKT have undergone pre-clinical evaluation with encouraging
results. Perifosine, an oral AKT inhibitor, is undergoing clinical
evaluation for malignant gliomas [11,15]. However, most clinical
trials of low molecular-weight kinase inhibitors as monotherapies
have failed to demonstrate survival benefit in unselected malignant
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agents with radiation or chemotherapy may overcome therapeutic
resistance and enhance treatment efficacy [11].
In this study, we compared the effect of a single treatment with
LY294002, a specific phosphatidylinositide-3-kinase (PI3K) inhib-
itor, or tamoxifen, a traditional cytotoxic chemotherapic agent,
with a combination treatment of the two agents on induction of
apoptosis in C6 glioma cells. The underlying mechanisms are
further explored in order to develop a novel and effective
therapeutic approach against malignant gliomas.
Materials and Methods
Chemicals and Antibodies
DMSO, tamoxifen and LY294002 were purchased from Sigma-
Aldrich,USA. Rabbit polyclonal antibodies against phospho-
AKT(Ser473), AKT(pan), GSK-3b (pan), phospho-GSK-3b, b-
catenin were purchased from Cell signal technology (USA).
Horseradish peroxidase-conjugated secondary antibody was
obtained from promega (USA); Alexa Fluor 488-conjugated goat
anti-rabbit antibody was from Molecular Probes; Nuclear
Extraction Kit was from Active Motif (USA); TUNEL Kit was
from Beyotime (Jiangsu, China); Antifade Solution was from
Applygen Technologies Inc (Beijing, China); Enhanced chemilu-
minescence (ECL) kit was from GE Healthcare (USA); EDTA-free
protease inhibitor was from Roche.
Cell treatment and plate colony formation assays
Rat C6 glioma cell (ATCC cat. number CCL-107), U251, and
U87 purchased from the China Center for Type Culture
Collection of Chinese Academy of Sciences were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
fetal bovine serum, 100 Units/ml penicillin and 100 mg/ml
streptomycin. Cells were seeded in 60 mm plates at a density of
5610
5 cells/ml and incubated overnight. The cells were serum-
starved for 24 h and followed by treatment with LY294002 or/
and tamoxifen. Control cells were incubated with vehicle only
(DMSO) at a concentration equal to that in drug-treated cells (final
concentration 0.1%). For combination experiments, quiescent cells
were treated with LY294002 with additional tamoxifen at various
concentrations at indicated times.
After 12 h treatment with LY294002, or/and tamoxifen, U251
cells were seeded into six-well plates (100 cells per well) and
cultured for 14 days. The plates were stained with Giemsa, and the
colonies were quantified. Each experiment was repeated in
triplicate.
Transfection of PI3K p85 siRNA and Western blot
U251 glioma cells were cultured in a 6-well plate (6610
5 cells/
well) overnight and transfected with PI3K p85 siRNA or control
non-targeted siRNA (Guangzhou RIBOBIO, CO., LTD) with
lipofectamine TM 2000 (Invitrogen) according to the manufac-
turer’s instruction. Following transfection, cells were collected for
Western blotting for p85 PI3K or treated with tamoxifen (5 mmol/
L) for 12 h for flow cytometric analysis.
After different treatments, cells were washed three times with
cold PBS and lysed in RIPA buffer on ice. Equivalent amounts of
protein (20 mg) from the soluble fractions of the cell lysates were
separated by 10% SDS–PAGE gel electrophoresis, and transferred
to PVDF membrane (Amersham Biosciences, Little Chalfont,
UK). After blocking with 5% nonfat milk in TBS containing
0.05% Tween 20 for 1 h, the membranes were incubated with
appropriately diluted primary antibodies at 4uC overnight, and
then probed with horseradish peroxidase–conjugated secondary
antibodies at 1:10,000 for 1 h at room temperature. Immunore-
active bands were detected by enhanced chemiluminescence and
visualized with the Las4000 (GE Healthcare). The intensities of the
blots were quantified by densitometry using MULTI GAUGE
software according to manufacturer’s instruction.
Apoptosis assay
Hoechst 33342 staining: Nuclear DNA in treated cells
contained in 24-well plates was visualized by staining with the
DNA-specific dye Hoechst 33342 at a final concentration of 5 mg/
ml. Cells were observed immediately with filters for blue
fluorescence.
TUNEL staining: Treated cells grown on 8-well chamber slides
were washed twice with PBS, and then fixed with 4%
paraformaldehyde in PBS for 60 min at room temperature. After
permeabilization with 0.1% Triton-X-100 (Sigma-Aldrich) for
2 min on ice, cells were stained with TUNEL reagent (Beyotime)
for 60 min at room temperature in the dark for in situ apoptosis
detection. Coverslips were mounted in Prolong Gold anti-fade
reagent with DAPI (Molecular Probes) and inspected with a Zeiss
710 confocal microscope.
Flow Cytometric Analysis : After treatment, detached cells and
harvested cells were labeled by annexin V-FITC/PI (propidium
iodide) apoptosis detection kit (KeyGEN Biotech) according to the
manufacturer’s instruction. Apoptotic and necrotic cells were
quantified by flow cytometer (Becton Dickinson, USA) and
analysis by the CellQuest software. At least 10,000 cells were
analyzed for each sample.
Immunofluorescence staining
C6 glioma cells were treated with 20 mmol/L of LY294002, or
5 mmol/L of tamoxifen, or with combined 20 mmol/L of
LY294002 and 5 mmol/L of tamoxifen for 30 min. Cells were
fixed with 4% paraformaldehyde in PBS (15 min, room
temperature), blocked for 30 min with10% normal goat serum
in PBS containing 0.1% saponin, and incubated with primary
antibodies diluted in blocking buffer (b-catenin, 1:1000) for 1 h at
room temperature. After washing with PBS, cells were incubated
with Alexa 488 Fluor-labeled secondary antibodies (diluted
1:1,000 in blocking buffer) for 1 h and washed with PBS.
Coverslips were mounted in Prolong Gold anti-fade reagent with
DAPI (Molecular Probes) and inspected with a confocal
microscope (Zeiss 710).
Preparation of Nuclear Extracts
Proteins in the nuclei of treated cells were extracted by Nuclear
Extract Kit (Active Motif; USA) according to the manufacturer’s
instructions. Cells were washed twice with ice-cold PBS containing
phosphatase inhibitors, and collected by gently scraping with cell
lifters. Cell pellets were lysed in Hypotonic Buffer and followed by
centrifugation at 50006 g for 5 min at 4uC. Nuclei were re-
suspended in lysis buffer and vortexed for 10 seconds at the
highest setting, followed by incubation for 30 minutes in ice on a
rocking platform set at 150 rpm. After centrifugation at 14,0006g
for 10 minutes at 4uC, the supernatants were collected as nuclear
extracts.
Quantitative Real-Time PCR
Quantitative Real-Time polymerase chain reaction (PCR) was
conducted using standard procedures [16]. Total RNA was
extracted using Trizol Reagent (Invitrogen, Carlsbad, CA, USA)
and reverse-transcribed into cDNA (Takala) according to the
manufacturer’s instructions. Quantitative real time PCR was
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China) in iCycler iQ thermocycler (Bio-Rad). The profile of
thermal cycling consisted of initial denaturation at 95uC for 30 s,
and 40 cycles at 95uC for 5 s and 60uC for 20 s. All primers used
for Real-Time PCR analysis were synthesized by Invitrogen. The
specificity of each primer pair was confirmed by melting curve
analysis and agarose-gel electrophoresis. b-actin was used as
internal control. Sequences of primers (59 to 39): for Survivin,
forward- TTGCTCCTGCACCCCAGAGC, reverse-AGGCT-
CAGCGTAAGGCAGCC; for BCL-xL, forward-CTTCTCCT-
TTGGCGGGGCACTG, reverse-TCCACAAAAGTGTCCCA-
GCCGCC; for BCL-2, forward-CTCTCGTCGCTACCGTCG-
CG, reverse-AGGCATCCCAGCCTCCGTTATCC; for Mcl-1,
forward-TGGAGGTGAACCCGACTTCCATG, reverse-TGG-
GGCTGGCTTGAGGTTCTCAA; for b-actin, forward-TCGT-
GCGTGACATTAAAGAG, reverse-ATTGCCGATGATAGT-
GATGACCT.
Results
Combination treatment with LY294002 and tamoxifen
significantly inhibited the proliferation of glioma cells
The ability of combination treatment with LY294002 and
tamoxifen to inhibit proliferation of U251 glioma cells was
examined by plate colony formation assay. The number of
colonies in controls and treated groups was counted and is
summarized in Fig. 1. From these results it was evident that U251
cells receiving combination treatment exhibited much lower
colony forming ability than those treated with LY294002 or
tamoxifen alone. Tamoxifen (2.5, 5, 10 mmol/L) combined with
10 mmol/L LY294001 does-dependently inhibited colony forma-
tion (39%, 22%, 13% respectively, Fig. 1A). However, combina-
tion of LY294001 at 10 or 20 mmol/L with Tamoxifen (5 mmol/L)
had a similar effect on colony formation (27%, 22% respectively,
Fig. 1B).
LY294002 enhanced the sensitization of glioma cells to
tamoxifen-induced apoptosis
The effect of LY294002 on tamoxifen-induced apoptosis was
evaluated by flow cytometric analysis, Hoechst staining, and
TUNEL analysis. Annexin V-FITC/propidium iodide staining
followed by flow cytometric analysis of apoptosis in C6, U251 and
U87 glioma cells treated with LY294002 (10 mmol/L), or/and
tamoxifen (5 mmol/L) revealed that the combination treatment
significantly increased the early apoptotic cells (Annexin V+/PI2,
Fig. 2).
Apoptotic cells demonstrating nuclear condensation and DNA
fragmentation can be detected by Hoechst 33342 staining and
fluorescence microscopy. As illustrated in Fig. 3A, C6 glioma cells
with combined treatment of LY294002 (20 mmol/L) and tamox-
ifen (5 mmol/L) for 24 h exhibited much more cells with
condensed and fragmented nuclei than those treated with
LY294002 or tamoxifen alone. Similar results were shown by
TUNEL analysis (Fig. 3B). Fragmented DNA in nuclei was
revealed as a green fluorescence signal. As shown in Fig. 1B,
combination treatment with 20 mmol/L of LY294002 and
5 mmol/L of tamoxifen for 24 h showed predominantly increased
DNA fragmentation compared with a single treatment with either
LY294002 or tamoxifen.
PI3K signaling pathway activation protected U251 cells
from apoptosis induced by combination treatment of
LY294002 and tamoxifen
Since the inhibition of PI3K enhanced the sensitization of
glioma cells to tamoxifen-induced apoptosis, we then studied
whether the activation of PI3K signaling pathway could protect
U251 cells from apoptosis induced by the combination treatment?
As shown in Fig. 4, the early apoptotic cells were significantly
increased by combination treatment with LY294002 (10 mmol/L)
and tamoxifen (5 mmol/L) compared with single treatment; and
Activation PI3K signaling pathway by IGF-1 (50 ng/ml) obviously
decreased the early apoptotic cells induced by combination
treatment (Fig. 2A and B).
PI3K-P85 siRNA enhanced the sensitization of U251
glioma cells to tamoxifen -induced apoptosis
To further confirm the involvement ofPI3K signalingpathway in
sensitizationof glioma cellsto tamoxifen-induced apoptosis,we then
examined the effect of PI3K signaling pathway interferenceby short
interfering RNA (siRNA) duplexes targeting the PI3K subunit p85.
Three different siRNA duplexes were tested, and S2 had the highest
efficiency (Fig. 5A) and was used for further experiments. Depletion
p85 by S2 siRNA in U251 cells increased the early apoptotic cells
(19%, Fig. 5B and C). This effect was much enhanced by 5 mmol/L
Figure 1. Colony formation assay with U251 cells receiving LY294002, tamoxifen, or the LY294002/tamoxifen combination. After
12 h treatment with LY294002 (LY), or/and tamoxifen (TAM), U251 cells were seeded into six-well plates (100 cells per well) and cultured for 14 days.
The plates were stained with Giemsa, and the colonies were quantified. A. Effect of combination treatment with different concentration (2.5, 5,
10 mmol/L) of TAM and 10 mmol/L LY; B. Effect of combination treatment with different concentration of LY (5, 10, 20 mmol/L) and 5 mmol/L TAM.
doi:10.1371/journal.pone.0027053.g001
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that the inhibition of PI3K signaling pathway could sensitize glioma
cells to tamoxifen-induced apoptosis.
Combination treatment with LY294002 and tamoxifen
significantly decreased Akt
Ser473 and GSK-3b
Ser9
phosphorylation in C6 glioma cells
To understand the molecular mechanisms by which LY294002
combined with tamoxifen resulted in increased apoptosis of C6
glioma cells, the levels of phosphorylated Akt
Ser473 and GSK-3b
Ser9
were compared after 12 hours single or combined treatment with
LY(20 mmol/L)or/and tamoxifen(2.5,5,10 mmol/L).Asshownin
Fig. 6, both phosphorylated Akt
Ser473 and GSK-3b
Ser9 were
decreased by LY294002 treatment, but were not affected by single
tamoxifen treatment. After a combination treatment with
LY294002 and tamoxifen, both phosphorylated Akt
Ser473 and
GSK-3b
Ser9 were significantly decreased (Fig. 6). Compared with
LY294002 single treatment, combination treatment significantly
reduced GSK-3b
Ser9 phosphorylation in a dose (tamoxifen)-
dependent manner (Fig. 6B, p,0.01).
Time-course changes of phosphorylated Akt
Ser473 and
GSK-3b
Ser9 after single or combined treatment with
LY294002 or/and tamoxifen
To evaluate the effects of combined treatment on phosphory-
lated Akt
Ser473 and GSK-3b
Ser9, immunoblotting was performed
with specific antibodies against phosphorylated Akt
Ser473 and
GSK-3b
Ser9 using extracts from C6 glioma cells treated with
LY294002 (20 mmol/L), or tamoxifen (5 mmol/L), or with a
combined treatment of LY294002 (20 mmol/L) and tamoxifen
(5 mmol/L) for various times (3, 6, 9, 12, 15 and 24 h). Our results
showed that although LY294002 single treatment and combined
treatment could keep phosphorylated Akt
Ser473 at lower levels
within 24 h (Fig. 7), combined treatment was much more efficient
in inhibiting GSK-3b
Ser9 phosphorylation (Fig. 7). Compared with
LY294002 single treatment, cells with combined treatment
revealed a significant reduction of phosphorylated GSK-3b
Ser9
within 24 h (Fig. 7B). Tamoxifen single treatment had no obvious
effects on phosphorylated Akt
Ser473 and GSK-3b
Ser9 in the
observed period (Fig. 7).
Figure 2. Flow cytometric analysis of apoptosis in C6, U251 and U87 glioma cells treated with LY294002 (LY), or/and tamoxifen
(TAM). C6, U251 and U87 cells were treated with 10 mmol/L LY, or/and 5 mmol/L tamoxifen for 12 h, followed by Annexin V-FITC/propidium iodide
staining. Columns representing the flow cytometry data presented in left. Data are means 6S.E.M. of values from three independent experiments;
FL2-H, propidium iodide; FL1-H, Annexin V.
doi:10.1371/journal.pone.0027053.g002
Figure 3. LY294002 enhanced the sensitization of C6 glioma
cells to tamoxifen-induced apoptosis. C6 glioma cells were treated
with PI3K inhibitor LY294002 (LY, 20 mmol/L), or/and tamoxifen (TAM,
5 mmol/L) for 24 h. The DMSO-treated cells were used as a control. After
treatment, cells were subjected to the following experiments. A.
Hochest 33342 staining; B. TUNEL staining. The apoptotic cells were
marked by green fluorescence; Scale bar, 20 mm.
doi:10.1371/journal.pone.0027053.g003
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upon drug treatment, we then studied the changes of phosphor-
ylated Akt
Ser473 and GSK-3b
Ser9 after combined treatment at
shorter times (15, 30, 60, 180 min). As shown in Fig. 4A,
phosphorylated Akt
Ser473 was rapidly decreased after 30 min of
combined treatment, and then slightly increased following the time
of combined treatment (Fig. 8A). Interestingly, phosphorylated
GSK-3b
Ser9 was reduced by combined treatment in a time-
dependent manner (Fig. 8A). Comparative studies showed that a
combination treatment for 30 min reduced the phosphorylated
GSK-3b
Ser9 level more effectively than LY294002 or tamoxifen
single treatment (Fig. 8B).
Effect of LY294002 pretreatment combined with
tamoxifen on the nuclear translocation of b-catenin in C6
glioma cells
To detect whether increased apoptosis of C6 glioma cells caused
by combined treatment of LY294002 and tamoxifen was
modulated by GSK-3b/b-catenin signaling pathway, nuclear b-
catenin was measured by western-blotting and confocal micros-
copy. As shown in Fig. 9A, nuclear b-catenin level was rapidly
reduced by a combination treatment for 30 min, then slightly
recovered after 60 min. Compared with LY294002 or tamoxifen
single treatment, a combined treatment could significantly inhibit
the translocation of b-catenin into the nucleus (Fig. 9B). Confocal
microscopy also confirmed much less nuclear staining of b-catenin
in cells with combined treatment than those with LY294002 or
tamoxifen single treatment (Fig. 9C).
Effect of combination treatment with LY294002 and
tamoxifen on the expression of anti-apoptotic genes
Because combined treatment could inhibit the translocation of
b-catenin into nucleus, we therefore investigated the mRNA levels
of anti-apoptotic genes that were possibly regulated by GSK-3b/
b-catenin signaling pathway, such as survivin, Bcl-XL, Bcl-2, and
Mcl-1. Our results showed that LY294002 single treatment for
12 h resulted in a remarkable increase of Bcl-2 and survivin
mRNA, which was up-regulated after only 4 h of LY294002
treatment; A slight increase of Bcl-XL and Mcl-1 mRNA was also
observed after 12 h of LY294002 single treatment, but failed to
reach statistic significance (Fig. 10A). Tamoxifen single treatment
had no effect on Bcl-2 mRNA, but strongly induced mRNA
Figure 4. PI3K signaling pathway activation protected cells from apoptosis induced by combination treatment of LY294002 and
tamoxifen. U251 cells were treated with 10 mmol/L LY294002 (LY), or/and 5 mmol/L tamoxifen (TAM), or combination of LY and TAM with additional
IGF-1 (50 ng/ml) for 12 h, followed by Annexin V-FITC/propidium iodide staining. Columns representing the flow cytometry data presented in left.
Data are means 6S.E.M. of values from three independent experiments; FL2-H, propidium iodide; FL1-H, Annexin V.
doi:10.1371/journal.pone.0027053.g004
Figure 5. PI3K-P85 siRNA enhanced the sensitization of U251 glioma cells to tamoxifen -induced apoptosis. A. After 48 h transfection
with non-targeted (Nc), or PI3K-P85 (S1,S2 or S3) siRNA, or without siRNA (Mock), total cell lysates (20 mg) were subjected to Western blot analysis. B.
After 48 h transfection with non-targeted (Nc), or PI3K-P85 S2 siRNA, cells were treated without or with 5 mmol/L tamoxifen (TAM) for 12 h, followed
by Annexin V-FITC/propidium iodide staining. C. Columns representing the flow cytometry data presented in B. Data are means 6S.E.M. of values
from three independent experiments. FL2-H, propidium iodide; FL1-H, Annexin V.
doi:10.1371/journal.pone.0027053.g005
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treatment was bidirectional: increased after 4 h of treatment and
decreased after 12 h of treatment. A Slight decrease of Bcl-XL
mRNA was also seen after 12 h of tamoxifen treatment (Fig. 10A).
The message RNA levels in all four genes were significantly reduced
by 12 h of combination treatment. Interestingly, the effect on Mcl-1
mRNA was especially strong. An obvious decrease of Mcl-1 mRNA
was found after only 4 h of combined treatment (Fig. 10A). Western
blot analysis revealed that the changes of survivin, Bcl-XL, Bcl-2,
and Mcl-1 protein in C6 glioma cells treated with 10 mmol/L of
LY294002, or/and 5 mmol/L of tamoxifen for 24 h were similar as
the changes of mRNA (Fig. 10B).
Discussion
Collective data on the genetic and cellular mechanisms of
glioma survival, proliferation and invasion indicated that the
malignant tumor phenotype results from the dysfunction of
multiple interrelated growth-regulatory pathways. One of the
most important effectors of growth factor receptor signaling is
the PI3K-Akt pathway, which is activated by multiple growth
factor receptors and functions as a central signaling node for
the activation of downstream effectors. In malignant gliomas,
overexpression and constitutive activation of growth factor
receptors, such as EGF receptor and IGF-1 receptor, and
Figure 6. Combination treatment with LY294002 and tamoxifen remarkably decreased AKT and GSK-3b phosphorylation in C6
glioma cells. C6 glioma cells were treated with PI3K inhibitor LY294002 (LY, 20 mmol/L), or/and tamoxifen (TAM, 5 mmol/L) for 12 h. The DMSO-
treated cells were used as a control. Proteins (20 ug) from total cell lysate were separated by SDS-PAGE gel electrophoresis, and immunoblotted with
antibodies against Akt(pan), phosphorylated Akt
Ser473 (A), GSK-3b(pan), or phosphorylated GSK-3b
Ser9 (B), and followed by densitometry
quantification. Data are means6S.E.M. of values from three independent experiments. **p,0.01, ***p,0.001 vs single treatment with 2.5 mmol/L of
tamoxifen; ### p,0.001 vs single treatment with 5 mmol/L of tamoxifen; $$$ p,0.001 vs single treatment with 10 mmol/L of tamoxifen.
doi:10.1371/journal.pone.0027053.g006
Figure 7. Time-course changes of phosphorylated Akt
Ser473 and GSK-3b
Ser9 after 24 h of single or combined treatment with
LY294002 or/and tamoxifen. C6 glioma cells were treated with LY294002 (LY, 20 mmol/L), or/and tamoxifen (TAM, 5 mmol/L) for indicated times.
The DMSO-treated cells were used as a control. Proteins (20 ug) from total cell lysate were separated in SDS-PAGE gel, and immunoblotted with
antibodies against Akt(pan), phosphorylated Akt
Ser473, GSK-3b(pan), or phosphorylated GSK-3b
Ser9 (A), followed by densitometry quantification (B).
Data are means 6S.E.M. of values from three independent experiments.
doi:10.1371/journal.pone.0027053.g007
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such as PTEN, lead to overactivation of PI3K-AKT signaling
and its downstream signal transduction pathways. The over-
activated PI3K/Akt pathway not only plays a central role in
maintaining the aggressive malignant phenotype of gliomas, but
also mediates treatment resistance by promoting cellular
survival and inhibiting the induction of apoptosis. It, therefore,
became an attractive target for the treatment of malignant
glioma [17].
However, single-targeted therapeutics against PI3K/AKT
pathway has demonstrated only modest clinical benefits, which
may be attributed to high resistance caused by multiple
concomitantly activated pathways in gliomas [17]. Selecting
appropriate combinations of anticancer agents that can exert
synergistic cytotoxic interactions has been widely adopted and
utilized in preclinical and clinical studies [18]. In the present
study, we compared the proapoptotic effect of single-treatment
with LY294002, a specific PI3K inhibitor, or tamoxifen, a
traditional cytotoxic chemotherapic agent, with a combination
treatment of those two agents. Our results revealed that
LY294002 significantly enhanced the sensitization of tamoxi-
fen-induced apoptosis in C6, U251 and U87 glioma cells. To
understand the underlying molecular mechanisms, we then
investigated the activation of downstream effectors of the PI3K
signaling pathway. High levels of phosphorylated Akt
Ser473 was
found in C6 glioma cells. Moreover, GSK-3b, a protein that is
constitutively active in resting cells, was functionally inactivated
by phosphorylation. This observation is similar to the findings in
human glioma [19]. Although LY294002 treatment could
rapidly decrease the phosphorylation of Akt
Ser473,a n dm a i n t a i n
it at low levels within 24 h, the phosphorylation of GSK-3b
Ser9
remained at a higher levels (Fig. 7). Both phosphorylated
Akt
Ser473 and GSK-3b
Ser9 remained at high levels within 24 h
of tamoxifen single treatment (Fig. 8). Interestingly, combined
treatment with LY294002 and tamoxifen showed an even lower
level of phosphorylated Akt
Ser473 than LY294002 single treat-
ment. Phosphorylation of GSK-3b
Ser9 was quickly down-
regulated and continued to be inhibited within 24 h of
combination treatment (Fig. 7). Those results indicated that the
GSK-3b signaling pathway could be responsible for synergistic
cytotoxic effect of LY294002 and tamoxifen combination
treatment.
GSK-3b, a multifunctional serine-threonine protein kinase,
regulates numerous signaling pathways involved in diverse
cellular processes, including metabolism, cell cycle control,
proliferation, differentiation and apoptosis. Recently, the patho-
logic role of GSK3b in malignant brain tumor was investigated,
and it was found that it could protect glioblastoma cells from
apoptosis by promoting survival and proliferation [20]. GSK3b
also plays an important role in regulating differentiation and
growth arrest in malignant glioma cells and glioblastoma [21,22].
Specific pharmacologic GSK-3b inhibitors and siRNA knock-
down of GSK-3b reduced glioma cell motility [23]. GSK-3b,
therefore, was considered as a potential therapeutic target in
malignant glioma. As a well-established component of the Wnt/
b-catenin signalling pathway, GSK-3b directly determines the
stabilization of b-catenin by phosphorylation. In the absence of
Wnt activating signals, b-catenin is sequestered in the cytoplasm
by a multiprotein complex, which includes GSK-3b. In this state,
b-catenin is phosphorylated by GSK-3b, which targets it for
ubiquitination and proteolytic degradation [24]. Activation of
Wnt signaling inhibits the formation of the multiprotein complex,
and the phosphorylation of b-catenin by GSK-3b. As a result,
there is an accumulation of stabilized hypophosphorylated b-
catenin, which then translocates to the nucleus and associates
with transcription factors of the Lef/Tcf family to initiate the
expression of a broad range of genes, such as c-myc, cyclin
D1,and survivin [25]. Aberrant activation of Wnt/b-catenin
signaling was found to be involved in glioma development and
progression [26]. Knockdown of b-catenin by siRNA in human
U251 glioma cells inhibited cell proliferation and invasive ability,
and induced apoptotic cell death [27]. Recent evidence indicated
that b-catenin transcriptional-promoting activity is an important
way to induce a state of apoptosis resistance [28,29]. In the
present study, we showed a significant decrease of nuclear b-
catenin by combination treatment with LY294002 and tamox-
ifen. However, only a slight decrease was found in the cells of
single treatment with LY294002 or tamoxifen. These data
indicate that the synergistic apoptosis-inducing effect of
LY294002 and tamoxifen combination treatment could be
attributed to the release of apoptotosis resistance in b-catenin
signaling.
Antiapoptotic genes are the key factors in the development of
apoptosis resistance and are believed to play a crucial role in
chemotherapeutic drugs resistance. The inhibition of b-catenin
signaling by LY294002 and tamoxifen combination treatment led
us to study the changes of an important pro-survival gene,
Survivin. Survivin is controlled via the b-catenin-Tcf/Lef
pathway, and has attracted a great deal of interests because of
its up-regulation in most human tumors for tumor survival
[30,31]. Clinical studies reported that invariable over expression of
Survivin is associated with resistance to chemotherapy or radiation
therapy, and is linked to poor prognosis [32]. Our results showed
Figure 8. Combination treatment of LY294002 and tamoxifen
rapidly decreased Akt and GSK-3b phosphorylation in C6
glioma cells. A. C6 glioma cells were treated with combined LY294002
(20 mmol/L) and tamoxifen (5 mmol/L) for indicated times. The DMSO-
treated cells were used as a control. Proteins (20 ug) from total cell
lysate were separated in SDS-PAGE gel, and immunoblotted with
antibodies against total Akt(pan), phosphorylated Akt
Ser473,G S K -
3b(pan), or phosphorylated GSK-3b
Ser9, and followed by densitometry
quantification. Data are means 6S.E.M. of values from three indepen-
dent experiments. B. C6 glioma cells were treated with LY294002 (LY,
20 mmol/L), or/and tamoxifen (TAM, 5 mmol/L) for 30 min. The DMSO-
treated cells were used as a control. Proteins (20 ug) from total cell
lysate were subjected to SDS-PAGE gel electrophoresis, and immuno-
blotted with antibodies against Akt(pan), phosphorylated Akt
Ser473,
GSK-3b(pan), or phosphorylated GSK-3b
Ser9, and followed by densi-
tometry quantification. Data are means 6S.E.M. of values from three
independent experiments. **p,0.01 vs single treatment with 5 mmol/L
of tamoxifen.
doi:10.1371/journal.pone.0027053.g008
Sensitization of Glioma Cells to Tamoxifen
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e27053that Survivin mRNA was significantly decreased by LY294002
and tamoxifen combination treatment in response to the inhibition
of b-catenin signaling. However, a single-treatment with
LY294002 or tamoxifen resulted in a remarkable up-regulation
of Survivin, which may partly explain their weak effect on
apoptosis induction.
Figure 9. Effect of combined treatment with LY294002 and tamoxifen on the nuclear translocation of b-catenin in C6 glioma cells. A.
C6 glioma cells were treated with combined LY294002 (20 mmol/L) and tamoxifen (5 mmol/L) for indicated times. The DMSO-treated cells were used
as a control. The levels of b-catenin or GAPDH (loading control) in nuclear extracts were analysed by Western blotting and quantified by
densitometry. Data are means 6S.E.M. of values from three independent experiments. B. C6 glioma cells were treated with 20 mmol/L of LY294002
(LY), or/and 5 mmol/L of tamoxifen (TAM) for 30 min. The DMSO-treated cells were used as a control. The levels of b-catenin or GAPDH (loading
control) in nuclear extracts were analysed by Western blotting and quantified by densitometry. Data are means 6S.E.M. of values from three
independent experiments. **p,0.01 vs single treatment with 5 mmol/L of tamoxifen. C. C6 glioma cells were treated with 20 mmol/L of LY294002 (LY),
or/and 5 mmol/L of tamoxifen (TAM) for 30 min. The cells were fixed and immunereacted with anti-b-catenin antibody followed by incubation with
Alexa 488-labeled secondary antibody. Images were taken by a confocal microscope (Zeiss 710). Scale bar, 20 mm.
doi:10.1371/journal.pone.0027053.g009
Figure 10. Effect of combination treatment with LY294002 and tamoxifen on the expression of anti-apoptotic genes. A. C6 glioma
cells were treated with 20 mmol/L of LY294002 (LY), or/and 5 mmol/L of tamoxifen (TAM) for 4 or 12 h. The DMSO-treated cells were used as a control.
Total RNA was extracted and the mRNA levels of Survivin, Bcl-XL, Bcl-2 and Mcl-1 were analysised by quantitative real-time PCR. Data were presented
as fold change over control group. Data are means 6S.E.M. of values from three independent experiments. *p,0.05, ** p,0.01, ***p,0.001 vs
control. B. C6 glioma cells were treated with 10 mmol/L of LY294002 (LY), or/and 5 mmol/L of tamoxifen (TAM) for 24 h. The DMSO-treated cells were
used as a control. Total cell lysates were extracted and the levels of Survivin, Bcl-XL, Bcl-2 and Mcl-1 were analysed by Western blotting.
doi:10.1371/journal.pone.0027053.g010
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members Bcl-2, Bcl-xL, and Mcl-1. These were considered
key regulators of apoptosis [33]. Upregulated expression of
antiapoptotic proteins of Bcl-2 family members commonly
occurs in human malignancies, and is related with disease
maintenance and progression, chemotherapy resistance, and
poor clinical prognosis [34]. In the present study, the mRNA
levels of all three antiapoptotic Bcl-2 genes Bcl-2, Bcl-xL, and
Mcl-1 were significantly reduced by combination treatment of
LY294002 and tamoxifen. The decrease in Mcl-1 mRNA was
rapid and was the strongest. Mcl-1 was initially reported in
differentiating myeloid cells [35]. As a pro-survival protein, high
levels of Mcl-1 were detected in human malignancies such as in
prostate, breast, colon and lung [36], and appear to be a factor
i nt h er e s i s t a n c eo fs o m ec a n c e r types to conventional cancer
therapies [37]. Unlike the other members of the Bcl-2 family,
Mcl-1 has a very short half-life, which allows for either the rapid
induction or elimination in response to cell survival or cell death
events [38]. Therefore, through inhibition of its anti-apoptotic
function by down-regulation, its expression could prominently
increase chemotherapeutic sensitization and make Mcl-1-
dependent cells more susceptible to apoptosis [34,37,39]. It
has been reported that the activity of GSK-3b was required for
Mcl-1 degradation, which is an essential mechanism for GSK-
3b-induced apoptosis and contributes to GSK-3b-mediated
tumor suppression and chemosensitization [40,41]. In accor-
dance with those findings, our results indicated sensitization of
glioma cells to combination treatment with Ly294002 and
tamoxifen benefited from its inhibitory effects on antiapoptotic
gene expression.
Taken together, our data demonstrate that a specific PI3K
inhibitor LY294002 significantly enhanced the sensitization of
glioma cells to tamoxifen-induced apoptosis. We also showed that
the GSK-3b/b-catenin signaling pathway and related antiapopto-
tic genes play critical roles in regulating cell survival or cell death
events in malignant glioma cells, and are the key factors in the
development of apoptosis resistance. The inhibition of b-catenin
signaling pathway and down-regulated expression of antiapoptotic
genes is due to increased GSK-3b activity that might be
responsible for synergistic cytotoxic effect of LY294002 and
tamoxifen.
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